作者：
Alba,Font-Tello [1]
;
Nikolas,Kesten [2]
;
Yingtian,Xie [1]
;
Len,Taing [2]
;
Damir,Varešlija [1]
;
Leonie S,Young [2]
;
Anis A,Hamid [1]
;
Eliezer M,Van Allen [2]
;
Christopher J,Sweeney [3]
;
Evisa,Gjini [3]
;
Ana,Lako [1]
;
F Steven,Hodi [1]
;
Joaquim,Bellmunt [4]
;
Myles,Brown [1]
;
Paloma,Cejas [1]
;
Henry W,Long [5]
作者单位：
Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
[1]
Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
[2]
Endocrine Oncology Research Group, Department of Surgery, Royal College of Surgeons in Ireland (RCSI), Dublin, Ireland.
[3]
Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
[4]
Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
[5]
Department of Genitourinary Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
[6]
Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA. paloma_cejas@dfci.harvard.edu.
[7]
Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA. paloma_cejas@dfci.harvard.edu.
[8]
Translational Oncology Laboratory, Hospital La Paz Institute for Health Research (IdiPAZ) and CIBERONC, La Paz University Hospital, Madrid, Spain. paloma_cejas@dfci.harvard.edu.
[9]
Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA. henry_long@dfci.harvard.edu.
[10]
Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA. henry_long@dfci.harvard.edu.
[11]
DOI
10.1038/s41596-020-0340-6
PMID
32591768
发布时间
2021-01-15
换一批
换一批
